ŷRobot's Daily Market Scan: BLK, RLAY, ABT, ALHC, CAG

ŷRobot Research · July 21, 2026

Today's Highlights

• BLK: ŷRobot's fair-value model indicates a +9% gap for BlackRock Inc. as of 2026-07-20, with a bullish AI score trend.
• RLAY: Relay Therapeutics shows a -7% fair-value gap as of 2026-07-20, with a neutral chart signal.
• ABT: Abbott Laboratories presents a -9% fair-value gap as of 2026-07-20, with its chart model leaning bearish.

BlackRock Inc (BLK)

BlackRock Inc. operates in the FINANCIAL SERVICES sector as a global investment management corporation. As a large-cap financial institution, BlackRock's performance often reflects broader trends in capital markets, investor confidence, and the demand for diverse investment products, from ETFs to active management. Its scale and reach make it a bellwether for the health of the financial industry and global asset flows.

ŷRobot's fair-value model, a machine-learning system trained on historical financial data, estimates a company's intrinsic value by considering various fundamental metrics to project future cash flows and discount them back to the present. For BlackRock Inc., the model estimates a fair value of $1,150 as of 2026-07-20. When compared to its prior close of $1,050, this suggests a positive fair-value gap of +9% as of 2026-07-20, implying the stock may be trading below ŷRobot's calculated intrinsic value.

The chart model, another machine-learning system, analyzes historical price and volume patterns to classify current price action. It identifies recurring technical formations and trends, providing a qualitative signal about potential short-to-medium term price behavior. As of 2026-07-20, ŷRobot's chart model currently classifies BLK as "neutral / no strong signal," indicating that its price action does not strongly align with either bullish or bearish technical patterns at this time.

The AI composite score, ranging from 0 to 100, measures the degree of agreement between ŷRobot's various analytical models, including the fair-value and chart models. A higher score indicates stronger consensus among the models regarding the stock's potential direction, suggesting a more robust signal. BLK's AI composite score is 65/100 as of 2026-07-20, with the AI score direction noted as "bullish," suggesting a positive alignment across models.

Relay Therapeutics Inc (RLAY)

Relay Therapeutics Inc. is a mid-cap company within the HEALTHCARE sector, specifically focusing on biotechnology. The company utilizes a unique computational and experimental platform to discover and develop new medicines that address a range of diseases. The biotechnology segment is characterized by high innovation, significant research and development costs, and the potential for transformative medical breakthroughs, making it a dynamic and often volatile area of the market.

ŷRobot's fair-value model estimates a fair value of $17.90 for Relay Therapeutics Inc. as of 2026-07-20. With a prior close of $19.20, this results in a fair-value gap of -7% as of 2026-07-20. This negative gap suggests that, according to ŷRobot's fundamental valuation, the stock may be trading above its estimated intrinsic value at the time of analysis.

ŷRobot's chart model, which interprets price and volume data to identify technical trends, currently classifies RLAY as "neutral / no strong signal" as of 2026-07-20. This classification implies that the stock's recent trading patterns do not present a clear or compelling technical indication for either upward or downward movement based on the model's analysis of historical patterns.

The AI composite score for RLAY is 59/100 as of 2026-07-20, with an AI score direction of "neutral." This score indicates a moderate level of agreement among ŷRobot's models. A neutral direction suggests that while there is some consensus, it does not strongly favor a particular market trajectory based on the combined model outputs.

Abbott Laboratories (ABT)

Abbott Laboratories is a large-cap company operating in the HEALTHCARE sector, known for its diversified portfolio of medical devices, diagnostics, branded generic medicines, and nutritional products. As a global healthcare leader, Abbott's performance is influenced by factors such as healthcare spending trends, regulatory approvals for new products, and demographic shifts, particularly the aging global population. Its broad market presence makes it a significant player in the sector.

ŷRobot's fair-value model estimates a fair value of $92.60 for Abbott Laboratories as of 2026-07-20. When compared to its prior close of $102, this indicates a fair-value gap of -9% as of 2026-07-20. This negative gap suggests that the stock's current market price may be above ŷRobot's calculated intrinsic value based on its fundamental analysis.

As of 2026-07-20, ŷRobot's chart model currently classifies ABT as "model leans bearish." This classification suggests that the model's analysis of historical price and volume patterns indicates a tilt towards bearish technical signals, implying potential downward pressure based on the identified chart formations.

The AI composite score for ABT is 53/100 as of 2026-07-20, with an AI score direction of "neutral." This score reflects a relatively low to moderate level of agreement among ŷRobot's analytical models. The neutral direction indicates that while there's some consensus, it doesn't strongly point to a definitive market trend based on the combined model outputs.

Alignment Healthcare LLC (ALHC)

Alignment Healthcare LLC is a mid-cap company in the HEALTHCARE sector, specializing in Medicare Advantage plans. This segment of healthcare is experiencing significant growth due to the aging population and the increasing demand for comprehensive, coordinated care for seniors. Companies like ALHC are at the forefront of innovating healthcare delivery and payment models, making their performance sensitive to regulatory changes, competitive pressures, and enrollment trends in the Medicare Advantage market.

ŷRobot's fair-value model estimates a fair value of $25.70 for Alignment Healthcare LLC as of 2026-07-20. With a prior close of $21.10, this indicates a positive fair-value gap of +22% as of 2026-07-20. This substantial positive gap suggests that, according to ŷRobot's fundamental valuation, the stock may be trading significantly below its estimated intrinsic value.

As of 2026-07-20, ŷRobot's chart model currently classifies ALHC as "neutral / no strong signal." This classification suggests that the model's analysis of price and volume patterns does not yield a clear bullish or bearish technical indication, implying that the stock's recent trading behavior lacks a strong directional trend based on historical chart patterns.

The AI composite score for ALHC is 56/100 as of 2026-07-20, with an AI score direction of "neutral." This score indicates a moderate level of cross-model agreement. The neutral direction suggests that while there is some consensus among the models, it does not strongly indicate a specific market trajectory for the stock based on their combined outputs.

Conagra Brands, Inc. (CAG)

Conagra Brands, Inc. operates in the CONSUMER DEFENSIVE sector as a large food company. It produces and markets a variety of branded food products for supermarkets, restaurants, and foodservice establishments. The consumer defensive sector is generally considered less sensitive to economic cycles, as demand for essential goods like food tends to remain relatively stable. However, companies in this space face challenges from changing consumer preferences, private label competition, and input cost fluctuations.

ŷRobot's fair-value model estimates a fair value of $13.10 for Conagra Brands, Inc. as of 2026-07-20. Compared to its prior close of $14.70, this results in a fair-value gap of -10% as of 2026-07-20. This negative gap suggests that, based on ŷRobot's fundamental analysis, the stock may be trading above its estimated intrinsic value.

As of 2026-07-20, ŷRobot's chart model currently classifies CAG as "neutral / no strong signal." This classification indicates that the model's analysis of historical price and volume data does not present a clear technical bias, suggesting that the stock's recent market action is not strongly indicative of either bullish or bearish momentum based on identified chart patterns.

The AI composite score for CAG is 52/100 as of 2026-07-20, with an AI score direction of "neutral." This score suggests a lower-to-moderate level of agreement among ŷRobot's analytical models. The neutral direction indicates that the combined model outputs do not strongly point towards a particular market trend for the stock at this time.

ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.